公开(公告)号：KR1020130106786A

公开(公告)日：2013-09-30

申请号：KR1020130028982

申请日：2013-03-19

Applicant: 가톨릭대학교 산학협력단

Inventor： 조미라 ,  박민정 ,  이성희

IPC: A61K31/4704 ,  A61K35/28 ,  A61P37/00

CPC classification number: A61K31/4704 ,  A61K35/28 ,  Y10S514/825 ,  Y10S514/885 ,  Y10S514/886

Abstract: PURPOSE: A composition for preventing or treating immunization disease including bone marrow-derived suppressor cell and rebamipide effectively treats immunization reaction and inflammation, by reducing the level of an autoimmune antibody and accelerating the activation of immunodulatory T cells. CONSTITUTION: A composition for preventing or treating immunization disease includes bone marrow-derived suppressor cell and rebamipide. The marrow-derived suppressor cell and rebamipide accelerates or increase the activity of Regulatory T cell: Treg and decrease the concentration of IgG, IgG1, and lgG2a in blood. The marrow-derived suppressor cell and rebamipide reduces and suppress the expression of IL-17 which is the inflammatory cytokine. The composition includes 5x10^5-2x10^6 of the marrow-derived suppressor cells.

Abstract translation: 目的：用于预防或治疗免疫疾病的组合物，包括骨髓来源的抑制细胞和瑞巴派特，通过降低自身免疫抗体的水平并加速免疫调节T细胞的活化，有效治疗免疫反应和炎症。 构成：用于预防或治疗免疫疾病的组合物包括骨髓来源的抑制细胞和瑞巴派特。 骨髓来源的抑制细胞和雷巴米特加速或增加调节性T细胞：Treg的活性，并降低血液中IgG，IgG1和IgG2a的浓度。 骨髓来源的抑制细胞和瑞巴派汀可降低和抑制炎性细胞因子IL-17的表达。 该组合物包括5×10 5〜2×10 -6个骨髓来源的抑制细胞。

公开(公告)号：KR1020120095320A

公开(公告)日：2012-08-28

申请号：KR1020120016400

申请日：2012-02-17

Applicant: 가톨릭대학교 산학협력단

Inventor： 조미라 ,  조석구 ,  박민정 ,  임정연 ,  이성희 ,  임건일

IPC: A61K31/203 ,  A61K31/07 ,  A61P29/00 ,  A61P35/00

Abstract: PURPOSE: A cytoprotection composition for toxicity suppression of natural killer cells including retinal or retinoic acid are provided to reduce or suppress toxicity of the natural killer cells by including T-cells. CONSTITUTION: A cytoprotection composition for toxicity suppression of natural killer cells includes retinal or retinoic acid as an active ingredient. The retinal or retinoic acid suppresses or prevent the cytotoxin of the natural killer cell as reduction. 0.1-5 microM of the retinal or retinoic acid is included. The cytoprotection composition for toxicity suppression of natural killer cells comprises T-cells which are differentiated by processing the retinal or the retinoic acid and human adipose derived mesenchymal stem cells. The differentiated Thymusdependentlymphocyte(treg cell) and the human adipose derived mesenchymal stem cells are included at a rate of 1:0.01-1:0.03.

Abstract translation: 目的：提供用于毒性抑制天然杀伤细胞（包括视网膜或视黄酸）的细胞保护组合物，以通过包括T细胞来减少或抑制天然杀伤细胞的毒性。 构成：用于毒性抑制天然杀伤细胞的细胞保护组合物包括视黄醛或视黄酸作为活性成分。 视网膜或视黄酸抑制或预防自然杀伤细胞的细胞毒素作为还原。 包括0.1-5微米的视网膜或视黄酸。 用于天然杀伤细胞毒性抑制的细胞保护组合物包括通过加工视网膜或视黄酸和人脂肪来源的间充质干细胞分化的T细胞。 分化的胸腺依赖性淋巴细胞（treg细胞）和人脂肪来源的间充质干细胞以1:0.01-1:0.03的比率包含。